Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to ...

Sanofi says it has reached an agreement with Dren Bio that would see it take control of autoimmune disease treatment DR-0201, a bispecific antibody-based myeloid cell engager with the potential to ...

Sanofi will receive about €10 billion ... In March, for example we agreed to acquire DR-0201 from Dren Bio. This promising molecule strengthens our early pipeline in immunology.

Sanofi just last month agreed to pay $600 million to Dren Bio for a drug it hopes can “reset” the immune system. Earendil uses artificial intelligence to streamline drug discovery and speed up ...

In March, Sanofi penned a $1.6 billion agreement with Dren Bio for a CD20-directed antibody aimed at B-cell non-Hodgkin lymphoma. Sanofi—which co-markets the anti-inflammatory blockbuster ...

Sanofi to acquire Dren Bio's immunology unit Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...